Trials / Conditions / Myeloid Malignancies

Myeloid Malignancies

19 registered clinical trials studyying Myeloid Malignancies — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for All NCT07396480	First Affiliated Hospital of Zhejiang University	Phase 3
Recruiting	A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 ( NCT06930651	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Not Yet Recruiting	VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT NCT07052422	Nanfang Hospital, Southern Medical University	Phase 2 / Phase 3
Not Yet Recruiting	Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refra NCT06917105	Tongji Hospital	Phase 1 / Phase 2
Recruiting	A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated NCT06668584	M.D. Anderson Cancer Center	Phase 2
Withdrawn	MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies NCT06543511	Dana-Farber Cancer Institute	N/A
Recruiting	Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodep NCT06383572	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530	Prelude Therapeutics	Phase 1
Completed	Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocyt NCT05775406	Kymera Therapeutics, Inc.	Phase 1
Recruiting	A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabi NCT05796570	Franziska Wachter	Phase 2
Unknown	Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies NCT05807659	Sichuan University	Phase 2
Completed	Off-the-shelf NK Cells + SCT for Myeloid Malignancies NCT05115630	M.D. Anderson Cancer Center	Phase 2
Terminated	Study of Magrolimab Combinations in Participants With Myeloid Malignancies NCT04778410	Gilead Sciences	Phase 2
Completed	Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies NCT03270748	Gruppo Italiano Trapianto di Midollo Osseo	Phase 2
Unknown	A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies NCT02958384	Southwest Hospital, China	Phase 1 / Phase 2
Unknown	A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies NCT02958397	Southwest Hospital, China	Phase 1 / Phase 2
Unknown	Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT NCT02452697	Cristina Gasparetto	Phase 2
Completed	Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis NCT01731951	Geron Corporation	Phase 2
Terminated	Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation NCT01366612	Hackensack Meridian Health	Phase 3